Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome

Inclusion Criteria: * Recent hospitalization for acute coronary syndrome: Complies with the diagnostic criteria for acute coronary syndrome (non-ST-segment elevation myocardial infarction, acute ST-segment elevation myocardial infarction, and unstable angina within 72 hours of onset) * LDL-C level (meet one of the following conditions): 1. Prior to the study, patients who received intensive statins for more than 4 weeks (the same dose of statin therapy has been sustained for the past four weeks) with LDL-C levels ≥70 mg/dL (≥1.8 mmol/L) or non-HDL-C ≥100 mg /dL (≥2.6mmol/L) are included in the study; 2. Prior to the study, patients who received moderate-intensity statin therapy for more than 4 weeks (the same dose of statin therapy has been sustained for the past four weeks) with LDL-C levels ≥90 mg/dL (≥2.3 mmol/L) or non-HDL-C≥ 120mg/dL (≥3.1mmol/L) are included in the study; 3. Prior to the study, patients who do not receive statin therapy or who do not continue to receive statin with LDL-C ≥ 125 mg/dL (≥ 3.2 mmol/L) or non-HDL-C ≥ 155 mg/dL (≥ 4.0 mmol/L). * Being able to understand research requirements and sign informed consent Exclusion Criteria: * Unstable clinical status (hemodynamics or ECG instability) * Uncontrolled arrhythmia, defined as recurrent or symptomatic ventricular tachycardia and atrial fibrillation with rapid ventricular reaction that the drug cannot control within three months prior to screening * Severe renal insufficiency, defined as estimated glomerular filtration rate\<30ml/min/1.73m2 * Active liver disease or liver dysfunction, whether it is on the patient's medical record or defined as an increase in alanine aminotransferase or aspartate aminotransferase more than 3 times above the upper limit of normal * Records on statin or rosuvastatin (any dose) intolerance or other statin intolerance * Known allergies to contrast agents, heparin, aspirin, ticagrelor or clopidogrel * Known allergies to the supplements required for the use of the drug * Patients who have been treated with evolocumab or other PCSK9 inhibitors * Received cholesterol ester transfer protein inhibitors treatment 12 months prior to screening * Received systemic steroid or cyclosporine treatment in the past 3 months * Known infections, hemorrhages, metabolic or endocrine disorders as determined by the researchers * Patients who have been included in other studies * Patients with active malignant tumor in need of treatment * Women with fertility (age \<50 years, menstruation in the past 12 months), did not receive tubal ligation, oophorectomy or hysterectomy